Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The
revised dopamine hypothesis states that dopamine abnormalities in the mesolimbic and …

Molecular, genetic and pathological evidence suggests that deficits in GABAergic
parvalbumin-positive interneurons contribute to schizophrenia pathophysiology through …

Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults
at the time of the first psychotic episode of delusions and hallucinations. These positive …

An increasingly popular method of assessing cognitive functions in rodents is the automated
touchscreen platform, on which a number of different cognitive tests can be run in a manner …

The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as
phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had …

Ketamine's clinical use began in the 1970s. Physicians benefited from its safety and ability to
induce short-term anesthesia and analgesia. The psychodysleptic effects caused by the …

Microglia, the brain′ s resident immune cells, are phagocytes of the macrophage lineage
that have a key role in responding to inflammation and immune challenge in the brain. More …

Accumulating evidence points to altered GABAergic parvalbumin-expressing interneurons
and impaired myelin/axonal integrity in schizophrenia. Both findings could be due to …

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …

Early detection and intervention in schizophrenia requires mechanism-based biomarkers
that capture neural circuitry dysfunction, allowing better patient stratification, monitoring of …